22,320 Doximity, Inc. $DOCS Shares Acquired by Riverbridge Partners LLC

Riverbridge Partners LLC boosted its holdings in Doximity, Inc. (NYSE:DOCS) by 7.9% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 303,539 shares of the company’s stock after buying an additional 22,320 shares during the period. Riverbridge Partners LLC owned approximately 0.17% of Doximity worth $8,602,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Doximity during the 3rd quarter worth $45,000. Versant Capital Management Inc raised its position in shares of Doximity by 1,176.9% during the 3rd quarter. Versant Capital Management Inc now owns 1,826 shares of the company’s stock valued at $52,000 after acquiring an additional 1,683 shares during the last quarter. Nisa Investment Advisors LLC lifted its stake in shares of Doximity by 59.9% in the 3rd quarter. Nisa Investment Advisors LLC now owns 1,855 shares of the company’s stock valued at $53,000 after purchasing an additional 695 shares during the period. Fortitude Family Office LLC lifted its stake in shares of Doximity by 31,271.4% in the 3rd quarter. Fortitude Family Office LLC now owns 2,196 shares of the company’s stock valued at $62,000 after purchasing an additional 2,189 shares during the period. Finally, Parallel Advisors LLC lifted its stake in shares of Doximity by 111.0% in the 1st quarter. Parallel Advisors LLC now owns 2,560 shares of the company’s stock valued at $60,000 after purchasing an additional 1,347 shares during the period. 87.19% of the stock is owned by institutional investors.

Insider Activity

In related news, CAO Siddharth Sitaram sold 2,613 shares of the firm’s stock in a transaction on Wednesday, October 14th. The stock was sold at an average price of $30.68, for a total transaction of $80,166.84. Following the sale, the chief accounting officer owned 101,432 shares of the company’s stock, valued at approximately $3,111,933.76. This trade represents a 2.51% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Timothy S. Cabral sold 10,721 shares of Doximity stock in a transaction dated Thursday, November 5th. The stock was sold at an average price of $35.00, for a total value of $375,235.00. Following the transaction, the director owned 8,084 shares in the company, valued at approximately $282,940. This represents a 57.01% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 24,471 shares of company stock worth $761,545 over the last quarter. Corporate insiders own 31.80% of the company’s stock.

Doximity News Roundup

Here are the key news stories impacting Doximity this week:

• Positive Sentiment: Some analysts have raised Doximity’s price targets, including Canaccord Genuity to $40, and Needham reiterated its Buy rating. A recent report also highlighted adoption of Doximity’s AI search products by 16 of the top 20 pharmaceutical companies and 34% year-over-year growth in quarterly active workflow prescribers. Analyst price target report Doximity long-term investor takeaways
• Neutral Sentiment: Director Timothy Cabral sold 10,721 shares for about $375,000. The transaction was made under a pre-arranged Rule 10b5-1 plan, which may make it less informative as a signal about his current outlook. Insider transaction report
• Negative Sentiment: Multiple law firms publicized a securities class action covering shares purchased from August 8, 2024, through May 13, 2026, with a November 16 deadline to seek lead-plaintiff status. The complaint alleges Doximity misled investors about market-share losses, competition and advertising practices, including reliance on lower-engagement formats, as well as revenue and growth trends. These claims have not been proven, but the litigation adds uncertainty and could weigh on sentiment. Class action allegations and deadline Advertising disclosure allegations

Analysts Set New Price Targets

DOCS has been the topic of several recent research reports. Freedom Capital lowered Doximity from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 8th. Evercore set a $35.00 price objective on Doximity in a report on Tuesday, September 29th. Stifel Nicolaus set a $27.00 price objective on Doximity in a report on Tuesday, September 8th. Barclays increased their target price on Doximity from $20.00 to $27.00 and gave the company an “equal weight” rating in a research note on Friday, August 21st. Finally, JPMorgan Chase & Co. raised their target price on Doximity from $26.00 to $31.00 and gave the stock a “neutral” rating in a report on Friday, August 7th. Eight equities research analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat.com, Doximity presently has an average rating of “Hold” and a consensus target price of $30.45.

Doximity Stock Performance

Shares of NYSE DOCS opened at $32.45 on Wednesday. The stock has a market cap of $5.78 billion, a P/E ratio of 45.07, a P/E/G ratio of 34.25 and a beta of 1.29. The firm has a 50 day moving average price of $29.33 and a 200 day moving average price of $25.43. Doximity, Inc. has a 52-week low of $17.15 and a 52-week high of $54.04.

Doximity (NYSE:DOCS) last issued its earnings results on Thursday, November 5th. The company reported $0.36 EPS for the quarter, beating the consensus estimate of $0.19 by $0.17. The firm had revenue of $174.54 million during the quarter. Doximity had a net margin of 21.12% and a return on equity of 15.80%. The firm’s revenue for the quarter was up 3.6% on a year-over-year basis. During the same period in the previous year, the company posted $0.45 EPS. Analysts predict that Doximity, Inc. will post 0.74 earnings per share for the current fiscal year.

About Doximity

Doximity, Inc. operates a digital platform designed for medical professionals, including physicians and other clinicians. Its services support professional networking, medical news and research discovery, career development, and communication among healthcare professionals. The company also offers clinical workflow tools, including Doximity Dialer, which enables clinicians to make calls and conduct video visits using a work number, as well as digital fax and document services. Doximity provides marketing and recruitment solutions to healthcare organizations and life sciences companies.